Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31742325 | 0.87 | EPHX2 (0.38) | GPR88ACKR3EPHX2HTR2AMEN1 | |
| SCHEMBL924316 | 0.87 | EPHX2 (0.38) | GPR88ACKR3EPHX2HTR2AMEN1 | |
| SCHEMBL31742326 | 0.85 | EPHX2 (0.37) | GPR88ACKR3EPHX2HTR2AMCL1 | |
| SCHEMBL31742335 | 0.85 | EPHX2 (0.37) | GPR88ACKR3EPHX2HTR2AMCL1 | |
| SCHEMBL16585394 | 0.84 | HTR2A (0.39) | GPR88KDM1AACKR3EPHX2HTR2A | |
| SCHEMBL16585393 | 0.84 | HTR2A (0.39) | GPR88KDM1AACKR3EPHX2HTR2A | |
| SCHEMBL15806707 | 0.83 | GPR88 (0.45) | GPR88KDM1AKDM1BEPHX2MEN1 | |
| SCHEMBL5679527 | 0.83 | GPR88 (0.45) | GPR88KDM1AKDM1BEPHX2MEN1 | |
| SCHEMBL15797855 | 0.83 | GPR88 (0.45) | GPR88KDM1AKDM1BEPHX2MEN1 | |
| SCHEMBL5683647 | 0.80 | EPHX2 (0.52) | GPR88EPHX2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1565190-A4 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1565190-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | Bristol-Myers Squibb Company (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004047738-A2 | ARYLCYCLOPROPYLCARBOXYLIC AMIDES AS POTASSIUM CHANNEL OPENERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | KCNQ2, KCNQ5, KCNJ2 | GPR88 604/4885KDM1A 441/4885KDM1B 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.